Company intelligence / Profile preview

Lens

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Lens Therapeutics was a clinical-stage biopharmaceutical company focused on developing innovative ophthalmic therapies, specifically for the treatment of presbyopia. The company's lead program, Aceclidine, was designed as a pupil-selective miotic to improve near vision without the common side effects associated with other muscarinic agonists. Lens Therapeutics was founded by industry veterans with experience from Allergan and ForSight Labs. In 2022, the company was acquired by Harrow (formerly Harrow Health) to bolster their ophthalmic drug development pipeline.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Lens.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lens.

Explore the full profile